ME Desk 03 of 05

Middle East and Africa Peptide News

The Gulf, Israel, Egypt and Africa south of the Sahara: local production, approvals, access programmes and supply deals.

Stories: 2
Countries: 2
Latest: 23 Oct 2026

Country

Topic

Stories

2 stories

ETEthiopiaMoney23 Oct 2026

Kilitch Drugs Ethiopia sale funds a new Pen site with GLP 1 on the plan

Kilitch sells 100% of its Ethiopian cephalosporin unit to an Oromia state enterprise for $14 million, $12.855 million of it to Kilitch, to fund debt cuts and a phased Pen site with GLP-1 plans.

AEUnited Arab EmiratesMoney23 Oct 2026

Lilly Mubadala Bio deal adds a GLP 1 packaging stage at a KEZAD site in Abu Dhabi

Lilly and Mubadala Bio agreed localised packaging and logistics for Lilly GLP-1 medicines, including Mounjaro and Foundayo, at a KEZAD site in Abu Dhabi, rolled out in phases.

About this desk

The Middle East and Africa desk follows peptide medicines in the Gulf states, Israel, Jordan, Egypt, North Africa and Africa south of the Sahara. Much of the news here is about building local supply: insulin and GLP-1 packaging or filling sites in the Gulf, pen and injectables plants in East and North Africa, and agreements that let a regional company finish a medicine made elsewhere. Regulators across the region often lean on decisions taken in Europe or the United States, so a local approval can come quickly after one there, or many years later. Stories name the country and the partners involved and say plainly what was announced and what is only planned. Where a figure comes from a company statement rather than a regulator or a filing, the story says so. Public health programmes that change who can get insulin or a newer peptide medicine are filed here as well.